On February 15, 2024, Neurogene Inc. (the ?Company?) appointed Donna Cochener as Senior Vice President, General Counsel. Ms. Cochener previously served as the Interim Chief Executive Officer and General Counsel of the Company when it was known as Neoleukin Therapeutics Inc. and prior to the merger on December 18, 2023 between a wholly owned subsidiary of the Company and Neurogene Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.35 USD | -1.40% | +0.32% | +92.72% |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
Jun. 03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.72% | 492M | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel